Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has David Gruben's publication output changed over time?
ScholarIQpublication output · 2009–2022
Output grew0% over the shown period — from 1 works in 2009 to 1 in 2022.
1
2
2
3
2
1
1
2009201120122013201420202022
What are the most-cited papers on David Gruben?
ScholarIQmost cited works
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann, Joel M. Kremer, John J. Cush, Hendrik Schulze‐Koops, Carol A. Connell, John Bradley, David Gruben, Gene V. Wallenstein, Samuel H. Zwillich, Keith S. Kanik
New England Journal of Medicine. 20121,038 CitationsOPEN ACCESS
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen, Eun Bong Lee, Juan A. García Meijide, Sylke Wagner, Šárka Forejtová, Samuel H. Zwillich, David Gruben, Tamás Koncz, Gene V. Wallenstein, Sriram Krishnaswami, John Bradley, Bethanie Wilkinson
New England Journal of Medicine. 2012944 CitationsOPEN ACCESS
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Eun Bong Lee, Roy Fleischmann, Stephen Hall, Bethanie Wilkinson, John Bradley, David Gruben, Tamás Koncz, Sriram Krishnaswami, Gene V. Wallenstein, Chuanbo Zang, Samuel H. Zwillich, Ronald van Vollenhoven
New England Journal of Medicine. 2014779 CitationsOPEN ACCESS
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R Burmester, Ricardo Blanco, Christina Charles‐Schoeman, J. Wollenhaupt, Cristiano A. F. Zerbini, Birgitta Benda, David Gruben, Gene V. Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, Tamás Koncz, Koshika Soma, John Bradley, Charles A. Mebus
The Lancet. 2013725 Citations
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, Edward Keystone, Joel M. Kremer, Cristiano A. F. Zerbini, Myrna Cardiel, Stanley Cohen, Peter Nash, Yeong Wook Song, Dana Tegzová, Bradley T. Wyman, David Gruben, Birgitta Benda, Gene V. Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, John Bradley, Carol A. Connell, and the ORAL Scan Investigators
S132787887. 2013583 Citations
Related on ScholarIQ
Pfizer (United States)
Institution
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Paper
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Paper
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Paper
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Paper
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
Paper